SNCA and neurodegenerative disease: Consistent with these investigations and observations, detecting α-synuclein from neuronal exosomes from blood or CSF is the first step, while the next involves augmenting the alpha-synuclein content via RT-QuiC, which seems to vary in different neurodegenerative diseases, i.e., as in DLB at the prodromal stage and in MCI-LB in particular.